Rhumbline Advisers Has $1.10 Million Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Rhumbline Advisers raised its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 86.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 24,447 shares of the company’s stock after buying an additional 11,315 shares during the period. Rhumbline Advisers’ holdings in Disc Medicine were worth $1,102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of IRON. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Disc Medicine in the 2nd quarter valued at about $129,000. SG Americas Securities LLC boosted its holdings in shares of Disc Medicine by 44.2% during the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after acquiring an additional 1,247 shares during the period. ProShare Advisors LLC acquired a new position in shares of Disc Medicine in the first quarter valued at approximately $211,000. Fiduciary Trust Co bought a new position in shares of Disc Medicine during the fourth quarter worth approximately $234,000. Finally, Jump Financial LLC bought a new position in shares of Disc Medicine during the fourth quarter worth approximately $249,000. 83.70% of the stock is owned by institutional investors.

Disc Medicine Stock Down 1.0 %

IRON stock opened at $48.11 on Monday. The company’s 50-day moving average price is $47.05 and its two-hundred day moving average price is $42.98. The firm has a market cap of $1.19 billion, a P/E ratio of -14.23 and a beta of 0.59. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. Equities analysts predict that Disc Medicine, Inc. will post -4.19 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $70.00 price objective (up from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. Wedbush restated an “outperform” rating and issued a $57.00 price target on shares of Disc Medicine in a research note on Friday, August 9th. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research report on Monday, September 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $64.13.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.